

INTRABIOTICS PHARMACEUTICALS INC /DE  
Form SC 13G/A  
October 01, 2002

-----  
OMB APPROVAL  
-----

OMB Number: 3235-0145  
Expires: October 31, 2002  
Estimated average burden  
hours per response.....14.90  
-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMENDMENT NO. 2(1)

INTRABIOTICS PHARMACEUTICALS, INC.  
-----

(Name of Issuer)

Common Stock, \$.001 par value  
-----

(Title of Class of Securities)

46116T 10 0  
-----

(CUSIP Number)

September 3, 2002  
-----

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, SEE the NOTES).

POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

SEC 1745 (3-98)

1

-----  
 CUSIP NO. 46116T-10-0                                  13G                                  PAGE 2 OF 8 PAGES  
 -----

-----  
 1                NAME OF REPORTING PERSON  
                     I.R.S. IDENTIFICATION NO(S) . OF ABOVE PERSON(S) (ENTITIES ONLY)  
  
                     Tang Capital Partners, LP  
 -----

2                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
                     (a)  
                     (b) X - Joint Filing  
 -----

3                SEC USE ONLY  
 -----

4                CITIZENSHIP OR PLACE OF ORGANIZATION  
  
                     United States  
 -----

|              |   |                          |
|--------------|---|--------------------------|
| NUMBER OF    | 5 | SOLE VOTING POWER        |
| SHARES       |   | 2,088,900                |
| -----        |   |                          |
| BENEFICIALLY | 6 | SHARED VOTING POWER      |
| OWNED BY     |   | 0                        |
| -----        |   |                          |
| EACH         | 7 | SOLE DISPOSITIVE POWER   |
| REPORTING    |   | 2,088,900                |
| -----        |   |                          |
| PERSON       | 8 | SHARED DISPOSITIVE POWER |

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

WITH: 0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,088,900

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
5.5%

12 TYPE OF REPORTING PERSON  
PN

CUSIP NO. 46116T-10-0

13G

PAGE 3 OF 8 PAGES

1 NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)  
Tang Capital Management, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a)  
(b) X - Joint Filing

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
United States

|           |   |                   |
|-----------|---|-------------------|
| NUMBER OF | 5 | SOLE VOTING POWER |
| SHARES    |   | 2,088,900         |

|              |   |                     |
|--------------|---|---------------------|
| BENEFICIALLY | 6 | SHARED VOTING POWER |
| OWNED BY     |   | 0                   |

|           |   |                        |
|-----------|---|------------------------|
| EACH      | 7 | SOLE DISPOSITIVE POWER |
| REPORTING |   | 2,088,900              |

|        |   |                          |
|--------|---|--------------------------|
| PERSON | 8 | SHARED DISPOSITIVE POWER |
| WITH:  |   | 0                        |

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,088,900

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.5%

12 TYPE OF REPORTING PERSON

OO

CUSIP NO. 46116T-10-0

13G

PAGE 4 OF 8 PAGES

1 NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)

Kevin C. Tang

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a)  
(b) X - Joint Filing

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5 SOLE VOTING POWER

SHARES 2,088,900

BENEFICIALLY 6 SHARED VOTING POWER

OWNED BY 0

EACH 7 SOLE DISPOSITIVE POWER

REPORTING 2,088,900

PERSON 8 SHARED DISPOSITIVE POWER

WITH: 0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,088,900

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

5.5%

12 TYPE OF REPORTING PERSON

IN

CUSIP NO. 46116T-10-0

13G

PAGE 5 OF 8 PAGES

1 NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO(S) . OF ABOVE PERSON(S) (ENTITIES ONLY)

Oscar L. Tang

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a)  
(b) X - Joint Filing

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

|           |   |                   |
|-----------|---|-------------------|
| NUMBER OF | 5 | SOLE VOTING POWER |
| SHARES    |   | 273,000           |

|              |   |                     |
|--------------|---|---------------------|
| BENEFICIALLY | 6 | SHARED VOTING POWER |
| OWNED BY     |   | 103,000             |

|           |   |                        |
|-----------|---|------------------------|
| EACH      | 7 | SOLE DISPOSITIVE POWER |
| REPORTING |   | 273,000                |

|        |   |                          |
|--------|---|--------------------------|
| PERSON | 8 | SHARED DISPOSITIVE POWER |
| WITH:  |   | 103,000                  |

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

376,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

1.0%

12 TYPE OF REPORTING PERSON

IN

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

- (a) Name of Issuer: Intrabiotics Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices:  
1245 Terra Bella Avenue, Mountain View, CA 94043

ITEM 2.

- (a) Name of Person Filing: Tang Capital Partners, LP  
Tang Capital Management, LLC  
Kevin C. Tang  
Oscar L. Tang
- (b) Address of Principal Business Office or, if none, Residence:  
Tang Capital Partners, LP  
Tang Capital Management, LLC  
Kevin C. Tang  
4401 Eastgate Mall  
San Diego, CA 92121  
  
Oscar L. Tang  
c/o Reich & Tang Asset Management LLC  
600 Fifth Avenue, 8th Floor  
New York, NY 10020
- (c) Citizenship: United States
- (d) Title of Class of Securities: Common Stock, par value \$.001
- (e) CUSIP Number: 56116T 10 0

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TOSS.SS.240.13D-1(b), OR 240.13D-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a)  Broker or Dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  An investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance withss.240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance withss.240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance withss.240.13d-1(b)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance withss.240.13d-1(b)(1)(ii)(J)

Not applicable.

ITEM 4. OWNERSHIP

- (a) Amount Beneficially Owned as of September 3, 2002:

The aggregate number and percentage of securities to which this Schedule 13G relates is 2,464,900 shares, representing 6.6% of the 37,742,421 shares outstanding as reported by the

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

Issuer in its Form 10Q filed with the SEC on August 14, 2002.  
The Filing Persons beneficially own those securities set forth below:

|                              |                  |
|------------------------------|------------------|
| Tang Capital Partners, LP    | 2,088,900 shares |
| Tang Capital Management, LLC | 2,088,900 shares |
| Kevin C. Tang                | 2,088,900 shares |
| Oscar L. Tang                | 376,000 shares   |

(b) Percent of Class:

|                              |       |
|------------------------------|-------|
| Tang Capital Partners, LP    | 5.5%  |
| Tang Capital Management, LLC | 5.5%  |
| Kevin C. Tang                | 5.5%  |
| Oscar L. Tang                | 1.0 % |

6

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

|                              |                  |
|------------------------------|------------------|
| Tang Capital Partners, LP    | 2,088,900 shares |
| Tang Capital Management, LLC | 2,088,900 shares |
| Kevin C. Tang                | 2,088,900 shares |
| Oscar L. Tang                | 273,000 shares   |

(ii) Shared power to vote or to direct the vote:

|                              |          |
|------------------------------|----------|
| Tang Capital Partners, LP    | 0 shares |
| Tang Capital Management, LLC | 0 shares |
| Kevin C. Tang                | 0 shares |
| Oscar L. Tang                | 103,000  |

(iii) Sole power to dispose or to direct the disposition of:

|                              |                  |
|------------------------------|------------------|
| Tang Capital Partners, LP    | 2,088,900 shares |
| Tang Capital Management, LLC | 2,088,900 shares |
| Kevin C. Tang                | 2,088,900 shares |
| Oscar L. Tang                | 273,000 shares   |

(iv) Shared power to dispose or to direct the disposition of:

|                              |                |
|------------------------------|----------------|
| Tang Capital Partners, LP    | 0 shares       |
| Tang Capital Management, LLC | 0 shares       |
| Kevin C. Tang                | 0 shares       |
| Oscar L. Tang                | 103,000 shares |

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: If this statement is being filed to report the fact as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: Not Applicable

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: Not Applicable

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: See Item 12 of Cover Pages and Item 2 of this Amendment No. 1 to Schedule 13G. Tang Capital Partners, LP is the registered holder of the shares. Tang Capital Management, LLC is the general partner of Tang Capital Partners, LP. Kevin C. Tang is the Manager of Tang Capital Management, LLC. Kevin C. Tang is the son of Oscar L. Tang.

ITEM 9. NOTICE OF DISSOLUTION OF A GROUP: Not Applicable

7

ITEM 10. CERTIFICATION:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated as of September 30, 2002

Tang Capital Partners, LP  
By: Tang Capital Management, LLC

By: /s/ Kevin C. Tang  
-----  
Kevin C. Tang, Manager  
Tang Capital Management, LLC

By: /s/ Kevin C. Tang  
-----  
Kevin C. Tang, Manager

/s/ Kevin C. Tang  
-----  
Kevin C. Tang

/s/ Oscar L. Tang  
-----  
Oscar L. Tang

8

EXHIBIT I

TO

AMENDMENT NO. 2



Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

TO  
SCHEDULE 13G  
UNDER THE  
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), TANG CAPITAL PARTNERS, LP affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule is filed on its behalf.

TANG CAPITAL PARTNERS, LP  
By: Tang Capital Management, LLC

By: /s/ Kevin C. Tang  
-----  
Kevin C. Tang, Manager

9

EXHIBIT II  
TO  
AMENDMENT NO. 2  
TO  
SCHEDULE 13G  
UNDER THE  
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), TANG CAPITAL MANAGEMENT, LLC affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule is filed on his behalf.

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin C. Tang  
-----  
Kevin L. Tang, Manager

10

EXHIBIT III  
TO

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

AMENDMENT NO. 2  
TO  
SCHEDULE 13G  
UNDER THE  
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), KEVIN C. TANG affirms that he is individually eligible to use Schedule 13G and agrees that this Schedule is filed on his behalf.

/s/ Kevin C. Tang

-----  
KEVIN C. TANG

11

EXHIBIT IV  
TO  
AMENDMENT NO. 2  
TO  
SCHEDULE 13G  
UNDER THE  
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), OSCAR L. TANG affirms that he is individually eligible to use Schedule 13G and agrees that this Schedule is filed on his behalf.

/s/ Oscar L. Tang

-----  
OSCAR L. TANG

12